红日药业
(300026)
| 流通市值：107.35亿 | | | 总市值：117.76亿 |
| 流通股本：27.39亿 | | | 总股本：30.04亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,794,968,270.19 | 1,392,772,566.61 | 5,782,766,928.71 | 4,441,070,030.88 |
| 营业收入 | 2,794,968,270.19 | 1,392,772,566.61 | 5,782,766,928.71 | 4,441,070,030.88 |
| 二、营业总成本 | 2,663,577,969.56 | 1,309,581,769.19 | 5,589,472,668.86 | 4,202,854,621.74 |
| 营业成本 | 1,356,993,605.71 | 670,110,791.49 | 2,731,900,617.72 | 2,122,686,471.76 |
| 税金及附加 | 32,580,675.93 | 17,083,632.25 | 62,859,586.05 | 45,538,357.41 |
| 销售费用 | 966,616,775.09 | 468,639,182.17 | 2,119,531,668.47 | 1,546,879,956.41 |
| 管理费用 | 208,291,557.86 | 102,311,685.24 | 419,293,356.91 | 305,516,540.8 |
| 研发费用 | 92,911,178.5 | 47,479,993.23 | 228,544,840.55 | 154,099,892.09 |
| 财务费用 | 6,184,176.47 | 3,956,484.81 | 27,342,599.16 | 28,133,403.27 |
| 其中:利息费用 | 10,039,427.16 | 4,988,989.05 | 44,862,415.47 | 40,122,503.31 |
| 其中:利息收入 | 5,240,531.55 | 1,882,382.08 | 17,305,998.46 | 13,730,032.52 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -2,421,568.53 | -157,070.12 | -5,630,220.35 | -1,101,399.18 |
| 资产处置收益 | -1,887.72 | -2,775.47 | 1,079,388.94 | -63,974.29 |
| 资产减值损失(新) | -30,495,285.82 | -3,705,525.07 | -94,876,244.39 | -11,779,924.04 |
| 信用减值损失(新) | -6,587,868.94 | -11,288,468.12 | -99,027,937.48 | -50,473,991.06 |
| 其他收益 | 15,280,336.63 | 10,289,294.99 | 40,597,120.04 | 26,330,754.4 |
| 四、营业利润 | 107,164,026.25 | 78,326,253.63 | 35,436,366.61 | 201,126,874.97 |
| 加:营业外收入 | 5,177,635.11 | 1,251,014.25 | 42,817,877.39 | 12,257,304.99 |
| 减:营业外支出 | 3,028,332.04 | 2,699,690.64 | 24,269,709.12 | 11,467,516.86 |
| 五、利润总额 | 109,313,329.32 | 76,877,577.24 | 53,984,534.88 | 201,916,663.1 |
| 减:所得税费用 | 24,690,346.31 | 14,992,868.38 | 31,038,271.6 | 9,518,747.51 |
| 六、净利润 | 84,622,983.01 | 61,884,708.86 | 22,946,263.28 | 192,397,915.59 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 84,622,983.01 | 61,884,708.86 | 22,946,263.28 | 192,397,915.59 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 78,630,019.31 | 60,329,743.62 | 21,467,322.65 | 168,356,759.92 |
| 少数股东损益 | 5,992,963.7 | 1,554,965.24 | 1,478,940.63 | 24,041,155.67 |
| 扣除非经常损益后的净利润 | 69,179,649.82 | 54,859,203.97 | -7,607,061.84 | 157,861,165.48 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.03 | 0.02 | 0.01 | 0.06 |
| (二)稀释每股收益 | 0.03 | 0.02 | 0.01 | 0.06 |
| 八、其他综合收益 | 202,262.21 | 126,095.49 | 2,078,877.94 | -1,508,970.79 |
| 归属于母公司股东的其他综合收益 | 202,262.21 | 126,095.49 | 2,078,877.94 | -1,508,970.79 |
| 九、综合收益总额 | 84,825,245.22 | 62,010,804.35 | 25,025,141.22 | 190,888,944.8 |
| 归属于母公司股东的综合收益总额 | 78,832,281.52 | 60,455,839.11 | 23,546,200.59 | 166,847,789.13 |
| 归属于少数股东的综合收益总额 | 5,992,963.7 | 1,554,965.24 | 1,478,940.63 | 24,041,155.67 |
| 公告日期 | 2025-08-28 | 2025-04-28 | 2025-04-28 | 2024-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |